Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 5,501 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 5,501 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $30.74, for a total transaction of $169,100.74. Following the completion of the transaction, the insider owned 48,945 shares of the company’s stock, valued at approximately $1,504,569.30. The trade was a 10.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The stock was sold at an average price of $30.60, for a total transaction of $55,967.40.

Pharvaris Trading Up 0.7%

PHVS traded up $0.20 during midday trading on Tuesday, reaching $29.88. The company’s stock had a trading volume of 191,721 shares, compared to its average volume of 227,155. Pharvaris N.V. has a 1 year low of $15.46 and a 1 year high of $33.33. The stock’s 50-day moving average is $28.52 and its 200-day moving average is $26.90. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -9.40 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, equities research analysts forecast that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the business. Stempoint Capital LP raised its stake in shares of Pharvaris by 48.4% in the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock worth $2,447,000 after purchasing an additional 28,248 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in Pharvaris by 23.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock worth $2,981,000 after buying an additional 20,000 shares in the last quarter. Amundi raised its position in Pharvaris by 12.0% in the 1st quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after buying an additional 3,312 shares during the last quarter. Rock Springs Capital Management LP lifted its stake in Pharvaris by 3.6% during the 1st quarter. Rock Springs Capital Management LP now owns 645,533 shares of the company’s stock valued at $18,236,000 after acquiring an additional 22,131 shares during the period. Finally, SummitTX Capital L.P. boosted its holdings in shares of Pharvaris by 27.7% during the 1st quarter. SummitTX Capital L.P. now owns 29,184 shares of the company’s stock valued at $824,000 after acquiring an additional 6,325 shares during the last quarter.

Analyst Ratings Changes

Several research firms have commented on PHVS. Citizens Jmp dropped their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. UBS Group set a $74.00 price objective on shares of Pharvaris in a research report on Wednesday, May 13th. Finally, Wolfe Research initiated coverage on shares of Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pharvaris has a consensus rating of “Moderate Buy” and an average price target of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.